Bryn Mawr Capital Management LLC Acquires 4,178 Shares of Zoetis Inc. (NYSE:ZTS)

Bryn Mawr Capital Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 25.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,902 shares of the company’s stock after purchasing an additional 4,178 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Zoetis were worth $3,406,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new stake in Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC raised its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $157.38 on Friday. The firm has a market capitalization of $70.47 billion, a price-to-earnings ratio of 28.77, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The business has a fifty day simple moving average of $166.86 and a 200 day simple moving average of $178.14. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Sell-side analysts expect that Zoetis Inc. will post 6.06 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler decreased their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $214.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.